Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The role of enzyme replacement therapy in severe Hunter syndrome-an expert panel consensus.

European journal of pediatrics - 1 Jan 2012

Muenzer Joseph, Bodamer Olaf, Burton Barbara, Clarke Lorne, Frenking Gudrun Schulze, Giugliani Roberto, Jones Simon, Rojas Maria Verónica Muñoz, Scarpa Maurizio, Beck Michael, Harmatz Paul

Abstract excerpt

UNLABELLED: Intravenous enzyme replacement therapy (ERT) with idursulfase for Hunter syndrome has not been demonstrated to and is not predicted to cross the blood-brain barrier. Nearly all published experience with ERT with idursulfase has therefore been in patients without cognitive impairment (attenuated phenotype). Little formal guidance is available on the issues surrounding ERT in cognitively impaired...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disease Progression
Share to Enzyme Replacement Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Iduronate Sulfatase

Share to Mucopolysaccharidosis II

Share to Phenotype

Share to Practice Guidelines as Topic

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 22037758
DOI: 10.1007/s00431-011-1606-3
PMCID: PMC3249184

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The role of enzyme replacement therapy in severe Hunter syndrome-an expert panel consensus.PMID 22037758Read ↗

Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy.Semantic proximity Read ↗

Multidisciplinary management of Hunter syndrome.Semantic proximity Read ↗

Enzyme replacement therapy in two patients with an advanced severe (Hurler) phenotype of mucopolysaccharidosis I.Semantic proximity Read ↗

Initial report from the Hunter Outcome Survey.Semantic proximity Read ↗

Mortality and cause of death in mucopolysaccharidosis type II—a historical review based on data from the Hunter Outcome Survey (HOS)Semantic proximity Read ↗

Effect of Hunter disease (mucopolysaccharidosis type II) mutations on molecular phenotypes of iduronate-2-sulfatase: enzymatic activity, protein processing and structural analysis.Semantic proximity Read ↗

Analysis of long-term observations of the large group of Russian patients with Hunter syndrome (mucopolysaccharidosis type II).Semantic proximity Read ↗

Impact of ERT and Follow up of 17 Patients from the Same Family with Mild form of MPS IISemantic proximity Read ↗

Activities of daily living in patients with Hunter syndrome: impact of enzyme replacement therapy and hematopoietic stem cell transplantation.Semantic proximity Read ↗

The clinical phenotype of two patients with a complete deletion of the iduronate-2-sulphatase gene (mucopolysaccharidosis II--Hunter syndrome).Semantic proximity Read ↗

Portal hypertension in a patient with Hunter disease.Semantic proximity Read ↗

Evaluation of ADL in patients with Hunter disease using FIM score.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.